Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01421667 · ClinicalTrials.gov registry record · Phase 2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase 2 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT01421667 is a Phase 2 study that has completed, run by Seagen. The registered enrollment target is 176 participants.
The verdict
NCT01421667, a Phase 2 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A). The study will also evaluate the safety and efficacy of brentuximab vedotin in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Part B) as well as further evaluate correlation of CD30 expression and response in DLBCL (Part C).
Interventions
- DRUG brentuximab vedotin
- DRUG rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2011-08 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01421667
The ClinicalTrials.gov registry entry for NCT01421667 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which brentuximab vedotin is the first listed.
NCT01421667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01421667 about?
NCT01421667 is a clinical study titled "A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma". This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A). The study will also evaluate the safety and efficacy of brentuximab vedotin in combination with ...
What is the current status of trial NCT01421667?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2011-08. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01421667?
The interventions under investigation include: brentuximab vedotin (DRUG), rituximab (DRUG).
Who is sponsoring clinical trial NCT01421667?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.